Skip to main content

BiomX Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Months Ended September 30,
20242023
CASH FLOWS – OPERATING ACTIVITIES
Net loss(3,214)(20,678)
Adjustments required to reconcile cash flows used in operating activities:
Depreciation and amortization882659
Stock-based compensation1,083641
Amortization of debt issuance costs-453
Finance income, net(478)(293)
Revaluation of contingent consideration6(40)
Income from change in fair value of Private Placement Warrants(24,417)-
Private Placement Warrants issuance cost732-
Change in contract liability(1,976)-
Loss from sale and disposal of fixed assets, net145-
Goodwill impairment801-
Changes in operating assets and liabilities:
Other current and non-current assets(213)679
Trade accounts payable(2,691)241
Other accounts payable(1,169)3,354
Net change in operating leases(181)(60)
Net cash used in operating activities(30,690)(15,044)
CASH FLOWS – INVESTING ACTIVITIES
Cash and restricted cash acquired from the APT acquisition663-
Proceeds from short-term deposits-2,000
Proceeds from sale of property and equipment72-
Purchases of property and equipment(19)(43)
Net cash provided by investing activities7161,957
CASH FLOWS – FINANCING ACTIVITIES
Issuance of Private Placement Warrants under March 2024 PIPE28,745-
Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE21,269-
March 2024 PIPE issuance costs(507)-
Issuance costs from February 2023 PIPE-(333)
Issuance of Common Stock and Warrants under February 2023 PIPE-7,485
Pre-Funded Warrants exercise6-
Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs19-
Issuance cost from the APT acquisition(13)-
Repayment of long-term debt(10,747)(2,929)
Net cash provided by financing activities38,7724,223
Increase (decrease) in cash and cash equivalents and restricted cash8,798(8,864)
Effect of exchange rate changes on cash and cash equivalents and restricted cash(11)(37)
Cash and cash equivalents and restricted cash at the beginning of the period15,86432,294
Cash and cash equivalents and restricted cash at the end of the period24,65123,393
RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS
Cash and cash equivalents23,53722,450
Restricted cash1,114943
Total cash and cash equivalents and restricted cash24,65123,393
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest1,4371,455
Taxes paid1050
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment purchases included in accounts payable and Trade payable115
Issuance cost from March 2024 PIPE1,685-
Issuance of Common Stock under the APT acquisition3,041-
Issuance of Redeemable Convertible Preferred Shares under the APT acquisition12,610-
Issuance of Merger Warrants under the APT acquisition200-
Redeemable Convertible Preferred Shares conversion into shares of Common Stock13,774-
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.